Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery
NCT ID: NCT01820520
Last Updated: 2024-05-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
22 participants
INTERVENTIONAL
2013-01-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Membrane Blue Versus Infracyanine Green
NCT00555269
Safety and Efficacy Evaluation of Two Different Brilliant Blue G Dyes as Staining Agent in Vitreo Retinal Surgery.
NCT05086588
Post-surgical Functional Results in Patients With Epiretinal Membrane Undergoing Controlled Macular Detachment
NCT07095907
Transconjunctival Sutureless 25-Gauge Vitrectomy
NCT00870597
Brilliant Blue Versus Indocyanine Green
NCT01083004
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Double staining with brilliant blue G during vitrectomy
brilliant blue G
Double staining with brilliant blue G 0.025% for macular surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
brilliant blue G
Double staining with brilliant blue G 0.025% for macular surgery
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signing of informed consent
* Macular pathology requiring vitrectomy (epiretinal membrane, macular hole, vitreomacular traction syndrome)
Exclusion Criteria
* Known allergy to brilliant blue G
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asociación para Evitar la Ceguera en México
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asociación para Evitar la Ceguera en México
Mexico City, Mexico City, Mexico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RE11-09
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.